These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 36257383)
1. Histone deacetylase inhibitors as antidiabetic agents: Advances and opportunities. Sonthalia M; Roy BS; Chandrawanshi D; Ganesh GV; Jayasuriya R; Mohandas S; Rajagopal S; Ramkumar KM Eur J Pharmacol; 2022 Nov; 935():175328. PubMed ID: 36257383 [TBL] [Abstract][Full Text] [Related]
2. Phenylbutyrate and β-cell function: contribution of histone deacetylases and ER stress inhibition. Khan S; Komarya SK; Jena G Epigenomics; 2017 May; 9(5):711-720. PubMed ID: 28470097 [TBL] [Abstract][Full Text] [Related]
3. Exploring histone deacetylases in type 2 diabetes mellitus: pathophysiological insights and therapeutic avenues. Kumar KK; Aburawi EH; Ljubisavljevic M; Leow MKS; Feng X; Ansari SA; Emerald BS Clin Epigenetics; 2024 Jun; 16(1):78. PubMed ID: 38862980 [TBL] [Abstract][Full Text] [Related]
4. Histone deacetylases 1 and 3 but not 2 mediate cytokine-induced beta cell apoptosis in INS-1 cells and dispersed primary islets from rats and are differentially regulated in the islets of type 1 diabetic children. Lundh M; Christensen DP; Damgaard Nielsen M; Richardson SJ; Dahllöf MS; Skovgaard T; Berthelsen J; Dinarello CA; Stevenazzi A; Mascagni P; Grunnet LG; Morgan NG; Mandrup-Poulsen T Diabetologia; 2012 Sep; 55(9):2421-31. PubMed ID: 22772764 [TBL] [Abstract][Full Text] [Related]
5. Histone deacetylases and inhibitors in diabetes mellitus and its complications. Wang L; Bai Y; Cao Z; Guo Z; Lian Y; Liu P; Zeng Y; Lyu W; Chen Q Biomed Pharmacother; 2024 Aug; 177():117010. PubMed ID: 38941890 [TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitors: Future therapeutics for insulin resistance and type 2 diabetes. Sharma S; Taliyan R Pharmacol Res; 2016 Nov; 113(Pt A):320-326. PubMed ID: 27620069 [TBL] [Abstract][Full Text] [Related]
7. Protective role of sodium butyrate, a HDAC inhibitor on beta-cell proliferation, function and glucose homeostasis through modulation of p38/ERK MAPK and apoptotic pathways: study in juvenile diabetic rat. Khan S; Jena GB Chem Biol Interact; 2014 Apr; 213():1-12. PubMed ID: 24530320 [TBL] [Abstract][Full Text] [Related]
8. Valproic Acid Improves Glucose Homeostasis by Increasing Beta-Cell Proliferation, Function, and Reducing its Apoptosis through HDAC Inhibition in Juvenile Diabetic Rat. Khan S; Jena G J Biochem Mol Toxicol; 2016 Sep; 30(9):438-46. PubMed ID: 27079868 [TBL] [Abstract][Full Text] [Related]
9. The Emerging Role of HDACs: Pathology and Therapeutic Targets in Diabetes Mellitus. Dewanjee S; Vallamkondu J; Kalra RS; Chakraborty P; Gangopadhyay M; Sahu R; Medala V; John A; Reddy PH; De Feo V; Kandimalla R Cells; 2021 May; 10(6):. PubMed ID: 34071497 [TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors target diabetes via chromatin remodeling or as chemical chaperones? Lawless MW; O'Byrne KJ; Gray SG Curr Diabetes Rev; 2009 Aug; 5(3):201-9. PubMed ID: 19689255 [TBL] [Abstract][Full Text] [Related]
11. Role of HDAC inhibitors in diabetes mellitus. Makkar R; Behl T; Arora S Curr Res Transl Med; 2020 Apr; 68(2):45-50. PubMed ID: 31477543 [TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase 3 inhibition improves glycaemia and insulin secretion in obese diabetic rats. Lundh M; Galbo T; Poulsen SS; Mandrup-Poulsen T Diabetes Obes Metab; 2015 Jul; 17(7):703-7. PubMed ID: 25846481 [TBL] [Abstract][Full Text] [Related]
13. The Role of HDACs in the Response of Cancer Cells to Cellular Stress and the Potential for Therapeutic Intervention. Alseksek RK; Ramadan WS; Saleh E; El-Awady R Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897717 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of class II histone deacetylases in the spinal cord attenuates inflammatory hyperalgesia. Bai G; Wei D; Zou S; Ren K; Dubner R Mol Pain; 2010 Sep; 6():51. PubMed ID: 20822541 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of class I histone deacetylases unveils a mitochondrial signature and enhances oxidative metabolism in skeletal muscle and adipose tissue. Galmozzi A; Mitro N; Ferrari A; Gers E; Gilardi F; Godio C; Cermenati G; Gualerzi A; Donetti E; Rotili D; Valente S; Guerrini U; Caruso D; Mai A; Saez E; De Fabiani E; Crestani M Diabetes; 2013 Mar; 62(3):732-42. PubMed ID: 23069623 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of HDAC3 as a strategy for developing novel diabetes therapeutics. Meier BC; Wagner BK Epigenomics; 2014 Apr; 6(2):209-14. PubMed ID: 24811789 [TBL] [Abstract][Full Text] [Related]
17. Sodium butyrate mitigates type 2 diabetes by inhibiting PERK-CHOP pathway of endoplasmic reticulum stress. Hu Y; Liu J; Yuan Y; Chen J; Cheng S; Wang H; Xu Y Environ Toxicol Pharmacol; 2018 Dec; 64():112-121. PubMed ID: 30342372 [TBL] [Abstract][Full Text] [Related]
18. Histone Deacetylase Inhibitors as Multitarget-Directed Epi-Drugs in Blocking PI3K Oncogenic Signaling: A Polypharmacology Approach. Ranganna K; Selvam C; Shivachar A; Yousefipour Z Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33147762 [TBL] [Abstract][Full Text] [Related]
19. Inhibitory selectivity among class I HDACs has a major impact on inflammatory gene expression in macrophages. Cao F; Zwinderman MRH; van Merkerk R; Ettema PE; Quax WJ; Dekker FJ Eur J Med Chem; 2019 Sep; 177():457-466. PubMed ID: 31181405 [TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus. Christensen DP; Dahllöf M; Lundh M; Rasmussen DN; Nielsen MD; Billestrup N; Grunnet LG; Mandrup-Poulsen T Mol Med; 2011; 17(5-6):378-90. PubMed ID: 21274504 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]